# Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

> **NCT04268550** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 124 (estimated)

## Conditions studied

- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **DRUG:** Selpercatinib

## Key facts

- **NCT ID:** NCT04268550
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-04-08
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04268550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04268550, "Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04268550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*